Courtney Flaherty

Courtney Flaherty joined OncLive as an assistant editor in October 2022. Leveraging an educational background in the life sciences and prior experience conducting interviews in a university setting, she plays a key role in shaping social media strategy, covering live conferences, and producing multimedia content for both print and digital platforms. Email: cflaherty@onclive.com

Articles

CIRT Plus Durvalumab/Tremelimumab Is Safe in Advanced HCC With Macrovascular Invasion

August 8th 2024

CIRT plus durvalumab and tremelimumab was safe in patients with advanced hepatocellular carcinoma with macrovascular invasion.

Dr Bazhenova on Updated Data From the TRUST-I Trial of Taletrectinib in ROS1+ NSCLC

August 8th 2024

Lyudmila A. Bazhenova, MD, discusses updated efficacy data from the TRUST-I study of taletrectinib in ROS1-positive advanced non–small cell lung cancer.

Olomorasib Plus Pembrolizumab Generates Antitumor Activity in KRAS G12C+ NSCLC

August 8th 2024

Olomorasib plus pembrolizumab demonstrated responses in first-line metastatic KRAS G12C–mutant non–small cell lung cancer.

Merck Discontinues KeyVibe-008 Trial of Vibostolimab/Pembrolizumab Plus Chemo in ES-SCLC

August 8th 2024

The KeyVibe-008 trial evaluating vibostolimab, pembrolizumab, and chemotherapy in extensive-stage small cell lung cancer has been discontinued.

Dr Linscott on Future Directions for utDNA Research in Bladder Cancer

August 8th 2024

Joshua Linscott, MD, PhD, discusses a study investigating the use of utDNA to predict MRD prior to rTURBT in NMIBC.

Dr Saad on the Association Between IL-7 SNPs and Immune-Related AEs in RCC

August 8th 2024

Eddy Saad, MD, MSc, discusses the association between an IL-7 SNP and immune-related AEs in patients with RCC who received immune checkpoint inhibitors.

Leveraging ADCs in Lung Cancer: Snapshot of Existing Challenges and Opportunities

August 7th 2024

Kashul Parikh, MBBS, discusses research efforts dedicated to leveraging antibody-drug conjugates with varying targets in lung cancer.

EO-3021 Generates Responses in Advanced Solid Tumors Likely to Express CLDN18.2

August 6th 2024

EO-3021 was safe and led to responses in advanced, unresectable or metastatic solid tumors likely to express Claudin 18.2.

EMA Grants Orphan Drug Designation to SLS009 for R/R PTCL

August 6th 2024

The European Medicines Agency has granted orphan drug designation to SLS009 for relapsed/refractory peripheral T-cell lymphoma

FDA Accepts sNDA for Cabozantinib in Advanced Pancreatic and Extra-Pancreatic NETs

August 6th 2024

The FDA has accepted a supplemental new drug application for cabozantinib in advanced pancreatic and extra-pancreatic neuroendocrine tumors.

Residual Cancer Burden May Prognosticate Outcomes With Neoadjuvant Therapy in Prostate Cancer

August 6th 2024

Praful Ravi, MB, BChir, MRCP, discusses an analysis measuring residual cancer burden in localized prostate cancer after neoadjuvant therapy and surgery.

Epcoritamab Optimization Lowers Neurotoxicity, Boosts Outpatient Feasibility in Follicular Lymphoma

August 5th 2024

Julie M. Vose, MD, MBA, discusses results with epcoritamab from the follicular lymphoma cycle 1 optimization cohort of the phase 1/2 EPCORE NHL-1 trial.

Dr Bazhenova on Improving Biomarker Development in Lung Cancer

August 5th 2024

Lyudmila A. Bazhenova, MD, discusses steps that the lung cancer field can take to improve biomarker research.

Dr Florez on Addressing Key Gaps in Lung Cancer Care

August 5th 2024

Narjust Florez, MD, discusses the importance of addressing crucial gaps in care for patients with lung cancer.

PD-L1 Expression Remains Primary Guide for NSCLC Treatment Selection in the Absence of Targetable Mutations

August 5th 2024

Kaushal Parikh, MBBS, highlights how PD-L1 expression affects treatment decision-making in the absence of other targetable mutations or prognostic indicators in non–small cell lung cancer.

Refining Adjuvant Immunotherapy Use Is a Crucial Focus in Early-Stage NSCLC

August 2nd 2024

Kaushal Parikh, MBBS, discusses treatment advances in early-stage NSCLC including for patients with actionable mutations, and details considerations with adjuvant approaches.

Bladder-Sparing Treatment Post–Pembrolizumab Progression Is Effective in BCG-Unresponsive NMIBC

August 2nd 2024

Roger Li, MD, discusses the efficacy of bladder-sparing therapy after progression on pembrolizumab in patients with BCG-unresponsive, high-risk NMIBC.

BCMA/CD19–Targeting CAR T-Cell Therapy Is Effective in Newly Diagnosed Multiple Myeloma

August 2nd 2024

The BCMA/CD19–targeted CAR T-cell therapy GC012F was safe and produced favorable outcomes in newly diagnosed multiple myeloma after induction therapy.

Dr Riess on Treatment Developments in ALK+ and ROS1+ NSCLC

August 2nd 2024

Jonathan Wesley Riess, MD, MS, discusses developments in the treatment of patients with NSCLC harboring ALK or ROS1 rearrangements.

Dr Herbst on the Evolution of Targeted Therapies for EGFR+ NSCLC

August 2nd 2024

Roy S. Herbst, MD, PhD, discusses the evolution of targeted therapies in EGFR-mutated NSCLC, as well as hurdles associated with biomarker testing.